CAMBRIDGE, UK (2019-12-23) – ProteinLogic, the biomarker discovery and exploitation company, has been featured in GenomeWeb’s 360Dx diagnostics online, one of the leading diagnostics newsletters.
The article followed interviews with ProteinLogic’s CEO, Dr Nicolas Huber, and a clinical collaborator of the company representing ProteinLogic’s study consortium, Dr Marcelo Cordeiro-Santos, as well as other experts in the field of TB diagnosis. The results stated in the article refer to ProteinLogic’s extensive clinical validation of its novel, blood-based, host immune response diagnostic for the ruling-out of Active TB disease in cohorts of varied genetic background, also from patients co-infected with HIV. The article further discusses the critical need for such a test in the diagnostic arsenal, and how the ProteinLogic approach could have a significant impact in the fight to eradicate TB.
Dr Huber stated: “We are excited to be featured in such a prestigious online publication. This is testament to the significant work of ProteinLogic in TB, and our dedication to making a difference against this terrible disease. With the completion of our multi-site clinical validation that has definitively proven the clinical efficacy of our test, ProteinLogic’s work is building momentum towards a commercial release of our test to make it available to the clinical community. I would like to express my gratitude to our clinical collaborators across the globe, without whom our work would not have been possible.”
The full article can be found here (paywall).